^
    Apply
    A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors (NCT04353830)
    Phase 1a
    Innovent Biologics (Suzhou) Co. Ltd.
    Completed
    Last update posted :
    03/01/2023
    Initiation :
    05/22/2020
    Primary completion :
    05/11/2022
    Completion :
    05/11/2022
    TIGIT
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)